Trial Profile
Dose Response Evaluation of CHF 1535 HFA pMDI in Asthmatic Patients Using Lung Function, Adenosine Monophosphate Bronchial Challenge and Fractional Exhaled Nitric Oxide (FENO)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Beclometasone/formoterol (Primary)
- Indications Asthma
- Focus Therapeutic Use
- Sponsors Chiesi Farmaceutici
- 02 May 2011 New trial record